Published in World J Radiol on June 28, 2014
PET imaging biomarkers in head and neck cancer. Eur J Nucl Med Mol Imaging (2015) 0.83
Prognostic significance of monocarboxylate transporter expression in oral cavity tumors. Cell Cycle (2016) 0.77
The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature. Eur Arch Otorhinolaryngol (2015) 0.77
(18)F-FDG PET/CT quantification in head and neck squamous cell cancer: principles, technical issues and clinical applications. Eur J Nucl Med Mol Imaging (2016) 0.76
Imaging strategy for response evaluation to chemoradiotherapy of the nodal disease in patients with head and neck squamous cell carcinoma. Int J Clin Oncol (2015) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med (2003) 13.99
Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med (2004) 9.55
Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med (2004) 8.60
An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol (2003) 6.82
Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med (1991) 6.39
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
Standards for PET image acquisition and quantitative data analysis. J Nucl Med (2009) 4.37
Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol (2005) 4.37
Anatomy of SUV. Standardized uptake value. Nucl Med Biol (2000) 3.07
Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med (2004) 2.97
SUV: standard uptake or silly useless value? J Nucl Med (1995) 2.96
Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys (2004) 2.93
A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results. Int J Radiat Oncol Biol Phys (2001) 2.85
First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med (2012) 2.76
Influence of the blood glucose concentration on FDG uptake in cancer--a PET study. J Nucl Med (1993) 2.66
Detection of metastasis in cervical lymph nodes: CT and MR criteria and differential diagnosis. AJR Am J Roentgenol (1992) 2.64
Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2005) 2.41
Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer (2003) 2.37
Energy deregulation: licensing tumors to grow. Science (2006) 2.31
MRI-based attenuation correction for PET/MRI using ultrashort echo time sequences. J Nucl Med (2010) 2.23
Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys (2003) 2.10
Positron emission tomography-computed tomography standardized uptake values in clinical practice and assessing response to therapy. Semin Ultrasound CT MR (2010) 2.09
Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med (1991) 2.09
The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys (2005) 1.99
Intensity-modulated radiation therapy for head and neck carcinoma. Oncologist (2007) 1.94
MRI-based attenuation correction for hybrid PET/MRI systems: a 4-class tissue segmentation technique using a combined ultrashort-echo-time/Dixon MRI sequence. J Nucl Med (2012) 1.92
Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys (2005) 1.89
Diagnostic performance of post-treatment FDG PET or FDG PET/CT imaging in head and neck cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging (2011) 1.82
The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med (1994) 1.80
Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2009) 1.71
The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer (2004) 1.67
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer. J Clin Oncol (2009) 1.66
Utility of PET/CT imaging performed early after surgical resection in the adjuvant treatment planning for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.65
Clinical utility of PET/CT in the evaluation of head and neck squamous cell carcinoma with an unknown primary: a prospective clinical trial. Head Neck (2010) 1.62
Intensity-modulated radiation therapy in head and neck cancers: an update. Head Neck (2007) 1.60
Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med (1998) 1.58
Combined 18F-FDG-PET/CT imaging in radiotherapy target delineation for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2008) 1.53
Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 1.46
Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck (2005) 1.45
Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys (2006) 1.42
Quality of life after parotid-sparing IMRT for head-and-neck cancer: a prospective longitudinal study. Int J Radiat Oncol Biol Phys (2003) 1.39
Initial experience of FDG-PET/CT guided IMRT of head-and-neck carcinoma. Int J Radiat Oncol Biol Phys (2006) 1.32
Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future. Mol Imaging Biol (2012) 1.25
Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging (2009) 1.23
Cervical lymph node metastases of squamous cell carcinoma from an unknown primary. Cancer Treat Rev (2004) 1.21
Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys (2012) 1.18
FDG-PET/CT-guided intensity modulated head and neck radiotherapy: a pilot investigation. Head Neck (2005) 1.15
Head and neck squamous cell carcinoma (HNSCC)--detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging (2009) 1.14
Diagnosis and staging of head and neck cancer: a comparison of modern imaging modalities (positron emission tomography, computed tomography, color-coded duplex sonography) with panendoscopic and histopathologic findings. Arch Otolaryngol Head Neck Surg (2000) 1.11
Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. Eur J Nucl Med Mol Imaging (2011) 1.09
Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys (2010) 1.08
PET/MR imaging: technical aspects and potential clinical applications. Radiology (2013) 1.08
Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer (1988) 1.07
The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer (2005) 1.06
Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. Int J Radiat Oncol Biol Phys (2008) 1.03
FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma. Radiat Oncol (2008) 1.02
Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck (2001) 1.00
Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient. Laryngoscope (2000) 1.00
Health-related quality-of-life outcomes following IMRT versus conventional radiotherapy for oropharyngeal squamous cell carcinoma. Int J Radiat Oncol Biol Phys (2007) 0.96
Screening for distant metastases in patients with head and neck cancer: is there a role for (18)FDG-PET? Oral Oncol (2005) 0.95
Cost-effectiveness of CT and PET-CT for determining the need for adjuvant neck dissection in locally advanced head and neck cancer. Ann Oncol (2009) 0.95
The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma. Oral Oncol (2011) 0.95
Distant metastases and synchronous second primary tumors in patients with newly diagnosed oropharyngeal and hypopharyngeal carcinomas: evaluation of (18)F-FDG PET and extended-field multi-detector row CT. Neuroradiology (2008) 0.94
Prospective imaging assessment of mortality risk after head-and-neck radiotherapy. Int J Radiat Oncol Biol Phys (2010) 0.93
Staging of head and neck squamous cell cancer with extended-field FDG-PET. Arch Otolaryngol Head Neck Surg (2003) 0.92
Cost-effectiveness of positron emission tomography/computed tomography in the management of advanced head and neck cancer. J Otolaryngol Head Neck Surg (2011) 0.91
Expression of glucose transporter-1 and -3 in the head and neck carcinoma--the correlation of the expression with the biological behaviors. ORL J Otorhinolaryngol Relat Spec (2008) 0.91
[18FDG] PET-CT-based intensity-modulated radiotherapy treatment planning of head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 0.90
The prognostic value of hypoxia markers in T2-staged oral tongue cancer. Oral Oncol (2008) 0.90
Metabolic tumor volume as a prognostic imaging-based biomarker for head-and-neck cancer: pilot results from Radiation Therapy Oncology Group protocol 0522. Int J Radiat Oncol Biol Phys (2015) 0.88
Negative predictive value of surveillance PET/CT in head and neck squamous cell cancer. AJNR Am J Neuroradiol (2013) 0.87
Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope (2003) 0.87
Distant metastases in head-and-neck squamous cell carcinoma treated with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys (2011) 0.87
Impact of a second FDG PET scan before adjuvant therapy for the early detection of residual/relapsing tumours in high-risk patients with oral cavity cancer and pathological extracapsular spread. Eur J Nucl Med Mol Imaging (2012) 0.85
Clinical evaluation of patients with metastatic squamous carcinoma of the neck with occult primary tumor. South Med J (1986) 0.85
Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol (2003) 0.84
Sequential FDG-PET/CT after neoadjuvant chemotherapy is a predictor of histopathologic response in patients with head and neck squamous cell carcinoma. Mol Imaging Biol (2011) 0.81
Serial FDG-PET on patients with head and neck cancer: implications for radiation therapy. Int J Radiat Biol (2009) 0.80
The Application of FDG-PET as Prognostic Indicators in Head and Neck Squamous Cell Carcinoma. PET Clin (2012) 0.80
Diagnostic sensitivity of ¹⁸fluorodeoxyglucose positron emission tomography for detecting synchronous multiple primary cancers in head and neck cancer patients. Eur Arch Otorhinolaryngol (2011) 0.76
New Tracers PET in Head and Neck Squamous Cell Carcinoma. PET Clin (2012) 0.76